EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische Studie

Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2− breast cancer: The LINUXtrial

Lei Fan, Wen-Juan Zhang, Hui-Ping Li, Xiao-Hua Zeng, Yue-E Teng, Yue Gong, Xi Jin, Shen Zhao, Tao Sun, Wen-Yan Chen, Shu-Sen Wang, Jin Yang und 37 weitere

Cancer Cell · 2026-02 · 44 (2) · 355-365.e3

DOI: 10.1016/j.ccell.2025.11.003 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer Cell, 2026-02. Verfasst von Lei Fan und 48 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Key Laboratory of Breast Cancer in Shanghai, Shanghai 200032, China; Departmen…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Artificial Intelligence, Precision Medicine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China, Shanghai Anti-Cancer Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report the results of LINUX (NCT05594095), a multicenter, randomized, controlled phase II platform trial aiming to identify effective precision treatments for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer after resistance to cyclin-dependent kinase 4/6 inhibitor. A total of 105 patients were categorized into four similarity network fusion (SNF) subtypes by artificial intelligence-assisted classification and randomly assigned to receive subtyping-based precision therapy (N = 70) or treatment of physician's choice (N = 35). Results demonstrate superior primary endpoint of objective response rates in the subtyping-based groups compared to controls: 10% versus 0% for SNF1, 65% versus 30% for SNF2, 40% versus 30% for SNF3, and 70% versus 20% for SNF4. Grade 3-4 treatment-related adverse events occurred in 37% of both groups. These findings highlight the clinical benefits of subtyping-based precision therapies, particularly for SNF2 and SNF4 subtypes, warranting further validation in phase III trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesArtificial IntelligencePrecision MedicineHumansFemaleMiddle AgedAdultReceptors, EstrogenReceptors, ProgesteroneAgedTreatment OutcomeProtein Kinase Inhibitors

Stichwörter der Autor:innen

AI-assistedHR+/HER2−breast cancerprecision treatmentsubtyping-based therapy

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanReceptors, EstrogenReceptors, ProgesteroneProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Breast Surgery, Fudan University Shanghai Cancer Center, Key Laboratory of Breast Cancer in Shanghai, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 20…
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, China.
  • Department of Breast Cancer Center, Chongqing University Cancer Hospital, Chongqing 400015, China.
  • Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China.
  • Breast Internal Medicine Department, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang 110042, China.
  • Nanchang People's Hospital, Nanchang 330001, China.

Förderung

  • Science and Technology Commission of Shanghai Municipality
  • National Natural Science Foundation of China
  • Shanghai Anti-Cancer Association
  • Shanghai Shenkang Hospital Development Center
  • Jiangsu Hengrui Medicine
  • Shanghai Municipal Hospital Development Center
  • National Key Research and Development Program of China
  • Natural Science Foundation of Shanghai Municipality

Zitieren

APA

Fan, L., Zhang, W. J., Li, H. P., Zeng, X. H., Teng, Y. E., Gong, Y., Jin, X., Zhao, S., Sun, T., Chen, W. Y., Wang, S. S., Yang, J., Zhuang, Z. G., Ni, S. J., He, Z. X., Fu, D. Y., Song, C. G., Lv, Z., Liang, Q. N., …, & BCTOP investigators (2026). Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2− breast cancer: The LINUXtrial. Cancer Cell, 44(2), 355-365.e3. https://doi.org/10.1016/j.ccell.2025.11.003

Vancouver

Fan L, Zhang WJ, Li HP, Zeng XH, Teng YE, Gong Y, et al. Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2− breast cancer: The LINUXtrial. Cancer Cell. 2026;44(2):355-365.e3. doi:10.1016/j.ccell.2025.11.003

BibTeX
@article{Fan2026,
  author = {Fan, Lei and Zhang, Wen-Juan and Li, Hui-Ping and Zeng, Xiao-Hua and Teng, Yue-E and Gong, Yue and Jin, Xi and Zhao, Shen and Sun, Tao and Chen, Wen-Yan and Wang, Shu-Sen and Yang, Jin and Zhuang, Zhi-Gang and Ni, Su-Jie and He, Zhi-Xian and Fu, De-Yuan and Song, Chuan-Gui and Lv, Zheng and Liang, Qian-Nan and Yu, Bao-Hua and Shi, Jing and Wang, Nan and Liang, Xin-Rui and Zhang, Ning-Ning and Wang, Yun and Ji, Peng and Liu, Xi-Yu and Chen, Li and He, Min and Liu, Yin and Sui, Xin-Yi and Ma, Lin-Xiaoxi and Zhu, Xiu-Zhi and Yang, Fan and Ge, Li-Ping and Wu, Song-Yang and Wu, Jiong and Yu, Ke-Da and Liu, Guang-Yu and Hu, Xin and Shen, Yu and Pang, Zheng and Wang, Jian-Fei and Liang, Fei and Yang, Wen-Tao and Wang, Zhong-Hua and Jiang, Yi-Zhou and Shao, Zhi-Ming and BCTOP investigators, BCTOP investigators},
  title = {Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2− breast cancer: The LINUXtrial},
  journal = {Cancer Cell},
  year = {2026},
  volume = {44},
  number = {2},
  pages = {355--365.e3},
  doi = {10.1016/j.ccell.2025.11.003}
}
Kostenlos starten →